4.5 Review

Proteolytic and non-proteolytic roles of membrane type-1 matrix metalloproteinase in malignancy

Journal

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbamcr.2009.04.009

Keywords

Matrix metalloproteinase; Furin; LRP1; TIMP-2; Cell migration; Metastasis

Funding

  1. NIH [CA83017, CA77470, RR020843]
  2. Susan G. Komen Breast Cancer Foundation [BCTR123106]
  3. NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER
  4. NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR020843] Funding Source: NIH RePORTER
  5. NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK071956] Funding Source: NIH RePORTER

Ask authors/readers for more resources

This manuscript provides an overview of the dynamic interactions which play an important role in regulating cancer cell functions. We describe and discuss, primarily, those interactions which involve membrane type-1 matrix metalloproteinase (MT1-MMP), its physiological inhibitor tissue inhibitor of metalloproteinases-2 (TIMP-2), furin-like proprotein convertases and the low density lipoprotein-related protein 1 (LRP1) signaling scavenger receptor. The interaction among these cellular proteins controls the efficiency of the activation of MT1-MMP and the unorthodox intracellular signaling which is generated by the catalytically inert complex of MT1-MMP with TIMP-2 and which plays a potentially important role in the migration of cancer cells. Our in-depth understanding of these cellular mechanisms may provide the key to solving the puzzling TIMP-2 paradox. This unsolved paradox arises from the fact that TIMP-2 is a powerful inhibitor of MMPs including MT1-MMP, but at the same time high levels of TIMP-2 positively correlate with an unfavorable prognosis in cancer patients. Solving the TIMP-2 paradox may lead to solving a similar PAI-1 paradox and produce a clearer understanding of the biochemical mechanisms which control the functionality of the urokinase-type plasminogen activator.urokinase receptor.plasminogen activator inhibitor type-1 (uPAR.uPA.PAI-1) system in cancer. (C) 2009 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available